Garris C, et al. Qualitative patient-participant perspectives on implementation of cabotegravir and rilpivirine long acting (CAB+RPV LA) injectable in the US (CUSTOMIZE). Presented at IDWeek 2021, September 29 - October 3, 2021, Virtual Conference. Poster Presentation.
Zoom in or click an area to see more details.
Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have
not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Connect With Our Medical Experts
Request a Scientific Discussion
Submit a request for additional information from a ViiV Medical Expert.
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch